Crenolanib

Published

dm+d

Unassigned

New Medicines

Gastrointestinal stromal tumours (GIST) with a D842V mutation in PDGFRA gene

Information

New molecular entity
Arog Pharmaceuticals
Arog Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase
Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. They represent 0.1-3% of all gastrointestinal cancers. Estimated incidence is around 15 per million of population per annum. There are approximately 900 new cases per year in the UK [1].
Gastrointestinal stromal tumours (GIST) with a D842V mutation in PDGFRA gene
Oral

Evidence based evaluations

Acute myeloid leukaemia (AML) with FLT3 mutations

Information

New molecular entity
Arog Pharmaceuticals
Arog Pharmaceuticals

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase
AML is the most common acute leukaemia in adults. The incidence of AMLs in European adults is 5-8 cases per 100,000 [1].
Acute myeloid leukaemia (AML) with FLT3 mutations
Oral